Acasti Pharma (NASDAQ:ACST) Stock Price Passes Above 200 Day Moving Average of $2.74

Shares of Acasti Pharma Inc. (NASDAQ:ACST) passed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $2.74 and traded as high as $2.93. Acasti Pharma shares last traded at $2.93, with a volume of 2,465 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, Craig Hallum began coverage on Acasti Pharma in a research note on Wednesday, February 7th. They issued a “buy” rating and a $6.00 target price on the stock.

Acasti Pharma Stock Up 1.0 %

The company has a market capitalization of $27.53 million, a P/E ratio of -0.58 and a beta of 1.49. The business has a 50 day simple moving average of $3.33 and a 200-day simple moving average of $2.74.

Acasti Pharma (NASDAQ:ACST) last issued its quarterly earnings data on Monday, February 12th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.02. Equities analysts forecast that Acasti Pharma Inc. will post -1.44 EPS for the current fiscal year.

Acasti Pharma Company Profile

Acasti Pharma Inc engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company's lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.